AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
News
New alliance strives to advance human-based drug evaluation
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool have announced plans to work together on the development of next generation human cell models to advance human based drug discovery.
Entries now underway – showcase your talent alongside the best in the industry
The PharmaTimes International Clinical Researcher of the Year 2019 has been designed to recognise and reward the talent of entrants from all parts of the globe in this ultimate test.
AZ sells respiratory trio to Covis
AstraZeneca has handed over rights to a trio of non-core assets to Covis Pharma, as it continues to shed parts of its portfolio.
Priority review for Sanofi, Regeneron’s Dupixent
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
Social media scheme boosts breast cancer screening uptake
An NHS project using social media has driven a 13% increase in first time attendances for breast screening in Stoke-on-Trent over four years.
Health secretary throws his weight behind social prescribing
Health secretary Matt Hancock has announced plans to establish a National Academy for Social Prescribing to lead the practice under a renewed drive to improve the prevention of ill health.
US approves new use for BMS’ Empliciti
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Five new technology centres to drive earlier diagnoses
Business Secretary Greg Clark has announced five new centres of excellence for digital pathology and imaging in England, which will use advances in medical artificial intelligence to diagnose diseases at an earlier stage.
Health secretary unveils plans for greater focus on ill health prevention
Health secretary Matt Hancock is planning to breathe new life into the government’s approach to prevention of ill health, with a shift in focus to primary and community services.
Lilly says Trulicity cut risk of CV events in wide patient group
Lilly says its once-weekly diabetes drug Trulicity cut major adverse cardiovascular events (MACE) in patients taking part in the REWIND trial.
BIA gets green light to intervene in Actavis/ICOS patent case
The Supreme Court has given its consent to the UK’s BioIndustry Association (BIA) to intervene in a case that the latter says “could have far-reaching impacts on the life sciences sector”.
UK pharma Enesi links with Australian biotech Sementis
UK group Enesi Pharma has signed a deal with Australian biotech Sementis to develop solid dose versions of the latter’s lead peanut hypoallergy vaccine and its chikungunya/Zika vaccine candidates.
Pfizer’s new lung cancer drug bags US clearance
Pfizer’s new lung cancer treatment Lorbrena has bagged US approval for previously treated patients with a specific gene mutation and metastatic disease.
Sandoz dumps US filing for biosimilar rituximab
Novartis group Sandoz has decided not to pursue US submission of a biosimilar version of Roche’s Rituxan/Mabthera, after a request from regulators for more data.
